Buying the unique selling proposition

Although Cephalon Inc.'s planned acquisition of Salmedix Inc. for $160 million in cash plus $40 million in royalties is the company's first acquisition of a pure play cancer company, the deal fits CEPH's modus operandi of buying companies that have lead compounds with reduced risk profiles.

The 2000 acquisition of Anesta Corp. for $444 million in stock gave CEPH a marketed product: Actiq transmucosal fentanyl

Read the full 653 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE